FIRST WAVE BIOPHARMA
First Wave BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs in 2021 using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-1022 for COVID-19 gastrointestinal infections, and FW-420 for grade 1 Immune Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology patients.
FIRST WAVE BIOPHARMA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Brooklyn, New York, United States
Country:
United States
Website Url:
http://www.azurrx.com
Total Employee:
1+
Status:
Active
Contact:
(646)699-7855
Email Addresses:
[email protected]
Total Funding:
49.32 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS GoDaddy DNS Pound Sterling AWS Global Accelerator KnowBe4
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-09-16 | First Wave Bio | First Wave Bio acquired by First Wave BioPharma | 229 M USD |
Investors List
Alexander Capital
Alexander Capital investment in Post-IPO Equity - First Wave BioPharma
Official Site Inspections
http://www.azurrx.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "First Wave BioPharma"
AzurX
AzurX works with a diverse portfolio of space and advanced technology companies covering early-stage, growth and late stage ventures, advising on strategic partnerships, capability development, market development, …See details»
AzurX - Crunchbase Investor Profile & Investments
AzurX is a UAE-based investment and strategic space firm committed to advancing the state of humanity and human knowledge. AzurX is the trusted advisor and counselor to a growing …See details»
TEAM - AzurX
AzurX is backed by an accomplished team of experienced professionals, collaborators and strategic partners with diverse and differentiated expertise across sectors, industries, and geographies further deepening our …See details»
AzurX
STRATEGIC TECHNOLOGIES We support the development and growth of early-stage through to late-stage hard tech companies focused on space and strategic technologies. From Artificial …See details»
AzurRx BioPharma Announces Acquisition of First Wave Bio and its ...
Sep 13, 2021 AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and …See details»
AzurRx BioPharma Announces Acquisition of First Wave Bio
Sep 13, 2021 AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease …See details»
AzurRx BioPharma to Change Corporate Name to First Wave …
Sep 21, 2021 About First Wave BioPharma, Inc. First Wave BioPharma, Inc. (formerly AzurRx BioPharma, Inc.) is a clinical-stage biopharmaceutical company specializing in the …See details»
AzuRx BioPharma, Inc. - Trickle Research
Feb 7, 2018 Summary AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses …See details»
Organizational Culture for AzurRx BioPharma Inc
But AzurRx BioPharma Inc discourages such a model, and they focus on promoting femineity in the organization. To adopt femineity in the organizational culture, the company gives training …See details»
AzurRx BioPharma to Change Corporate Name to First Wave
Sep 21, 2021 AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September …See details»
INVESTMENTS - AzurX
AzurX collaborates and co-invests with strategic investment funds, as well as place direct investments in visionary founders and growth-stage ventures embedded in the space sector - …See details»
AzurRx BioPharma Company Profile 2024: Valuation, Investors ...
Information on acquisition, funding, cap tables, investors, and executives for AzurRx BioPharma. Use the PitchBook Platform to explore the full profile.See details»
AzurRx BioPharma - VentureRadar
"AzurRx BioPharma is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819-SD recombinant lipase for …See details»
AzurRx BioPharma Announces Closing of $5.75 Million Bought …
BOCA RATON, Fla., July 27, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing …See details»
AzurRx BioPharma Announces Exclusive Worldwide License
Jan 4, 2021 --AzurRx BioPharma, Inc.,, a company specializing in the development of non-systemic therapies for gastrointestinal diseases, today announced that it has signed an …See details»
AzurRx BioPharma Acquires First Wave Bio for $229 Million
Sep 16, 2021 AzurRx BioPharma, a company specializing in developing targeted, non-systemic therapies for gastrointestinal diseases (GI), announced that it has entered a definitive …See details»
Dubai-based space and technology investor AzurX backs Scottish ...
Sep 13, 2023 About AzurX AzurX, a Dubai-based professional services and investment firm for the space and satellite sector, is the chosen partner to emerging and leading commercial …See details»
AzurRx BioPharma Acquires First Wave Bio for $229 Million
Sep 16, 2021 AzurRx BioPharma, a company specializing in developing targeted, non-systemic therapies for gastrointestinal diseases (GI), announced that it has entered a definitive …See details»
AzurRx BioPharma Announces $3.0 Million Bought Deal Offering …
Jul 22, 2021 AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for …See details»
AzurRx BioPharma Announces WHO Publication of “Adrulipase
Aug 17, 2021 AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819 August 17, 2021 07:00 ET | Source: AzurRx …See details»